Burgos-Burgos Javier, Vega Víctor, Macias-Verde David, Gómez Virginia, Vicente Elena, Murias Carmen, Santana Carlos, Lara Pedro C
Canarian Comprehensive Cancer Center, San Roque University Hospital, 35001 Las Palmas de Gran Canaria, Spain.
Department of Medicine, Fernando Pessoa Canarias University, 35001 Las Palmas de Gran Canaria, Spain.
Cancers (Basel). 2024 Mar 9;16(6):1105. doi: 10.3390/cancers16061105.
The current standard of local treatment for patients with localized breast cancer (BC) includes whole breast irradiation (WBI) after breast-conserving surgery (BCS). Ultrahypofractionated WBI schemes (1-week treatment) were shown not to be inferior to the standard WBI. Tumor bed boost using photon intraoperative radiotherapy (IORT) is safe and feasible in combination with standard WBI. The aim of the present study is to assess, for the first time, the feasibility and safety of combining photon IORT with ultrahypofractionated WBI.
Patients diagnosed with low-risk early BC candidates for BCS were included in this prospective study. IORT was administered at a dose of 20 Gy to the surface's applicator, and WBI was administered 3-5 weeks after surgery at a total dose of 26 Gy in five consecutive days.
From July 2020 to December 2022, seventy-two patients diagnosed with low-risk early BC and treated in our institution were included in this prospective study. All patients completed the proposed treatment, and no severe acute or late grade 3 toxicity was observed 3 and 12 months after WBI, respectively.
Our results confirm for the first time that the combination of ultrafractionation WBI and photon-IORT after BCS is a feasible and safe option in patients with early BC.
局部乳腺癌（BC）患者当前的局部治疗标准包括保乳手术（BCS）后进行全乳照射（WBI）。超分割WBI方案（1周治疗）已被证明不劣于标准WBI。术中光子放疗（IORT）联合标准WBI对瘤床进行追加照射是安全可行的。本研究的目的是首次评估光子IORT与超分割WBI联合应用的可行性和安全性。
本前瞻性研究纳入了诊断为低风险早期BC且适合BCS的患者。IORT给予表面施源器20 Gy的剂量，WBI在术后3 - 5周进行，连续5天给予总剂量26 Gy。
2020年7月至2022年12月，本前瞻性研究纳入了72例在我院诊断为低风险早期BC并接受治疗的患者。所有患者均完成了拟行的治疗，WBI后3个月和12个月分别未观察到严重的急性或晚期3级毒性反应。
我们的结果首次证实，BCS后超分割WBI与光子IORT联合应用对早期BC患者是一种可行且安全的选择。
